Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus (NASDAQ:TEM) and Medtronic announced results from the ALERT trial on April 1, 2026 showing AI-driven EHR clinician notifications improved timely evaluation and treatment for significant aortic stenosis and mitral regurgitation.
The multicenter, cluster-randomized study (2,016 echocardiograms; 765 clinicians; 35 hospitals) met its primary endpoint (win ratio 1.27; P = .007) and showed a 40% relative increase in valve procedures (13.4% vs. 9.6%) within 90 days.
Tempus (NASDAQ: TEM) and Blood Cancer United announced a collaboration to build a large, patient-centered real-world registry for pediatric acute myeloid leukemia (pAML) using Tempus’ olivia app and Lens analytics.
The program will collect longitudinal patient‑reported outcomes, align educational materials to disease subtype and treatment stage, and enable de‑identified data access to support external control arms and accelerate pediatric AML research.
Tempus (NASDAQ: TEM) published a JCO Precision Oncology study (March 11, 2026) showing advanced comprehensive genomic profiling (CGP) features uncover clinically actionable findings missed by limited testing.
The study, in collaboration with The Oncology Institute, found 12% of patients had actionable findings tied to approved therapies identified solely via tumor-normal matching, RNA sequencing, and liquid biopsy reflex.
Authors argue CGP value extends beyond panel size and that guideline specificity on panel composition remains limited.
Tempus (NASDAQ:TEM) announced a multi-year strategic collaboration with Merck on March 3, 2026 to accelerate AI-driven precision medicine across oncology and potentially broader therapeutic areas. Merck will access Tempus’ de-identified multimodal data, Lens Platform, and Workspaces to train AI/ML models and discover precision biomarkers and resistance mechanisms.
The agreement leverages Tempus’ large GPU infrastructure for training-ready datasets, aiming to speed discovery, optimize candidate therapies, and inform rational combination strategies in Merck’s early pipeline.
Tempus (NASDAQ: TEM) will participate in the Morgan Stanley Technology, Media & Telecom Conference on Tuesday, March 3 in San Francisco. Founder and CEO Eric Lefkofsky will appear in a fireside chat at 9:15 AM PST.
A live webcast is available via the provided link and a recording will be posted on Tempus' Events page on its Investor Relations website.
Tempus (NASDAQ:TEM) reported strong fourth quarter and full year 2025 results, driven by diagnostics and data growth. Q4 revenue was $367.2M (+83.0% YoY) and full‑year revenue was $1.27B (+83.4% YoY). Gross profit rose to $797.9M for 2025.
The company closed 2025 with >$1.1B Total Remaining Contract Value, 126% net revenue retention, $759.7M in cash and marketable securities, and 2026 guidance of ~$1.59B revenue with ~ $65M Adjusted EBITDA.
Median Technologies (NASDAQ:TEM) received FDA 510(k) clearance for eyonis® LCS, an AI-powered SaMD for lung cancer screening, and appointed Oran Muduroglu as President of Median eyonis Inc. for U.S. commercialization.
The company has a non-exclusive distribution agreement with Tempus (TEM), a Medicare New Tech APC reimbursement pathway (~$601–$700 per exam for 2026), and expects first U.S. sites operational in Q3 2026. Approximately 14.5 million Americans meet USPSTF screening criteria, underpinning adoption potential.
Tempus (NASDAQ: TEM) launched its HRD-RNA algorithm, a 1,660-gene logistic regression model that assesses Homologous Recombination Deficiency via transcriptome analysis.
The RNA-based test aims to detect functional HRD where DNA genomic scarring may miss cases, expanding identification for platinum or PARP inhibitor therapies. A real-world validation in metastatic pancreatic cancer showed reduced mortality with platinum first-line therapy. HRD-RNA is research use only today; clinical availability is expected later this year.
Median Technologies (symbol: TEM) announced a non-exclusive distribution agreement with Tempus AI to expand U.S. access to eyonis® LCS after its FDA 510(k) clearance on February 9, 2026. The collaboration targets integration via the Tempus Pixel platform, leverages an NT-APC reimbursement pathway ($601–$700), and aims at 14.5 million eligible U.S. screening patients. Median expects CE marking in Q2 2026 and Tempus would support European rollout under the agreement.
Tempus (NASDAQ: TEM) announced a collaboration with Median Technologies to integrate eyonis® LCS into the Tempus Pixel platform on February 12, 2026. eyonis® LCS is an AI-based SaMD for lung cancer screening that received FDA 510(k) clearance earlier this month.
The integration will enable CT nodule detection, non-invasive characterization and a proprietary nodule malignancy score inside Tempus Pixel (an FDA-cleared, CE-marked imaging solution), aiming to help clinical teams prioritize patients and expand screening impact.